Entrada Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Entrada Therapeutics (TRDA).

Price Target Range — 9 Quarters

Analyst Consensus — 4 Analysts

3Buy

1Hold

Consensus RatingOutperform# Analysts4Avg. Consensus PT$23Upside to Avg. PT+309.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jun 8, 2026	Guggenheim	Debjit Chattopadhyay	PT Cut	Buy	$20→$17
May 8, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Downgrade	Buy→Neutral	—
Apr 6, 2026	Oppenheimer	Francois Brisebois	PT Raise	Outperform	$21→$23
Feb 18, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Feb 11, 2026	Guggenheim	Debjit Chattopadhyay	Initiate	Buy	$20
May 20, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Mar 31, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Feb 25, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Feb 4, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Dec 5, 2024	Roth MKM	Boobalan Pachaiyappan	Initiate	Buy	$29
Nov 6, 2024	Oppenheimer	Francois Brisebois	PT Raise	Outperform	$25→$28
Nov 6, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$18→$20
Aug 26, 2024	Oppenheimer	Francois Brisebois	Maintained	Outperform	$25
Aug 14, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$18
Jun 25, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$20→$18
Mar 18, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$20
Jan 5, 2024	Oppenheimer	Hartaj Singh	Initiate	Outperform	$22
Nov 27, 2023	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$25→$20

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Entrada Therapeutics, Lowers Price Target to $17

Guggenheim analyst Debjit Chattopadhyay maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy and lowers the price target from $20 to $17.

Benzinga Newsdesk

This HubSpot Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday

Wall Street analysts changed outlook on top names. Check all changes on analyst ratings page. See what analysts think about HUBS stock.

Avi Kapoor

PRO
HC Wainwright & Co. Downgrades Entrada Therapeutics to Neutral

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Entrada Therapeutics (NASDAQ:TRDA) from Buy to Neutral.

Benzinga Newsdesk

Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why

Entrada Therapeutics stock plunged after the Duchenne trial data missed investor expectations despite positive functional improvement signals.

Vandana Singh

PRO
Oppenheimer Maintains Outperform on Entrada Therapeutics, Raises Price Target to $23

Oppenheimer analyst Francois Brisebois maintains Entrada Therapeutics (NASDAQ:TRDA) with a Outperform and raises the price target from $21 to $23.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Buy and maintains $20 price target.

Benzinga Newsdesk

Entrada Therapeutics Inc

Entrada Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Entrada Therapeutics, Lowers Price Target to $17

This HubSpot Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday

PRO
HC Wainwright & Co. Downgrades Entrada Therapeutics to Neutral

Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why

PRO
Oppenheimer Maintains Outperform on Entrada Therapeutics, Raises Price Target to $23

PRO
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $20 Price Target

People Also Watch

People Also Watch

Entrada Therapeutics Inc

Entrada Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Maintains Buy on Entrada Therapeutics, Lowers Price Target to $17

This HubSpot Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday

PROHC Wainwright & Co. Downgrades Entrada Therapeutics to Neutral

Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why

PROOppenheimer Maintains Outperform on Entrada Therapeutics, Raises Price Target to $23

PROHC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $20 Price Target

People Also Watch

People Also Watch

PRO
Guggenheim Maintains Buy on Entrada Therapeutics, Lowers Price Target to $17

PRO
HC Wainwright & Co. Downgrades Entrada Therapeutics to Neutral

PRO
Oppenheimer Maintains Outperform on Entrada Therapeutics, Raises Price Target to $23

PRO
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $20 Price Target